Panacea Biotec has received long-term supply awards worth $127.30 million (around Rs 1,040 crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).
UNICEF award is worth $98.755 million (Rs 813 crore) for supply of 99.70 million doses during calendar years 2023-2027 and PAHO award is worth $28.55 million (Rs 235 crore) for supply 24.83 million doses during calendar years 2023-2025.
Paediatric vaccination plays an important role to achieve Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b - becoming the foundation of paediatric immunization programs across the world.
Easyfive-TT is the world's first fully liquid wP-based Pentavalent vaccine that as launched in India in 2005. After receiving WHO prequalification in 2008, more than 150 million doses have been supplied to over 75 countries globally. EasyFive-TT is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders.
As per Human Vaccines and lmmunotherapeutics, the fully-liquid Pentavalent vaccine has been hailed as a ‘breakthrough in India's Universal Immunisation Program’ with having averted more than 7 million cases, averted 31,000 deaths, and total benefits exceeding $1 billion in DALY savings in India.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1861.70 |
| Dr. Reddys Lab | 1389.35 |
| Cipla | 1506.15 |
| Lupin | 2228.00 |
| Zydus Lifesciences | 972.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
